People with spinal muscular atrophy demand urgent action from the Centre to reduce medicine costs
Health activists demand government action to reduce the cost of SMA medicines, citing constitutional obligations and ...
TheHealthSite9d
Raising Awareness On Spinal Muscular Atrophy: The Silent Battle Every Indian Should Know
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site ...
Man with degenerative disease pleads for Manitoba to cover treatment while it asks drug agency to review
A man with a muscle-wasting disease is pleased Manitoba is asking a federal agency to reconsider its opposition to a ...
SMA1d
Spinal cord gray matter may be imaging marker of SMA types 2, 3
More research is needed to confirm gray matter, the darker tissue found in the brain and spinal cord, “as a potential disease ...
‘Life After’ Review: An Empathetic and Confrontational Doc About Disabled People’s Right to Be in Control
Filmmaker Reid Davenport weaves a powerful first-person perspective with a journalistic investigation about disability ...
The American Journal of Managed Care13d
Phase 3 STEER Study of SMA Gene Therapy Meets Primary End Point
Patients with spinal muscular atrophy (SMA) type 2 showed improved motor ability when treated with intrathecal onasemnogene ...
The Week4d
Spinal muscular atrophy: Patients, activists seek health ministry’s intervention to bring down medicine cost
The health activists argue that the government is empowered with effective law and policy tools and therefore should ...
Managed Healthcare Executive5d
FDA and EMA Accepts Applications for New Nusinersen Regimen
An investigational higher dose of spinal muscular atrophy drug nusinersen gains attention as the FDA and European Medicines ...
Pharm Exec4d
Biogen Seeks FDA Approval for a Higher Dosing Regimen of Spinraza for Spinal Muscular Atrophy
Application is supported by results from the DEVOTE study, which suggested that two doses of Spinraza (nusinerse) 50 mg taken ...
Nasdaq5d
Biogen Inc. Announces FDA and EMA Acceptance of Higher Dose Regimen for Nusinersen in Spinal Muscular Atrophy
SPINRAZA is an approved treatment for spinal muscular atrophy in over 71 countries ... of the higher dose regimen in children and adults who transitioned from SPINRAZA 12 mg to the 50/28 mg ...
FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA
We are pleased to announce that our applications for the higher dose regimen of nusinersen are now under review in the US and Europe,” said Stephanie Fradette, Pharm.D., Head of the Neuromuscular ...